The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford supported by Parkinson’s UK with funding from The Monument Trust, one of the Sainsbury Family Charitable Trusts until 2021.
Established in February 2010, the OPDC brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Friday, 26 November 2021, 2pm to 3pm
Input zone-selective dysrhythmia in motor thalamus after dopamine depletion
MAGILL P. et al, (2021), The Journal of Neuroscience
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
Liu Y. et al, (2021), Mov Disord
Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.
Becker S. et al, (2021), Neurol Sci
Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
Okarmus J. et al, (2021), Stem Cell Reports, 16, 1510 - 1526
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Vijiaratnam N. et al, (2021), BMJ Open, 11
REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
Ryan BJ. et al, (2021), J Neurosci, 41, 3731 - 3746